Thank you for emphasizing the FDA's point of view of SOC treatment as a control arm.

some papers describe nanomedicine as that with particles that are less than 100nm (nanoparticles). So it seems that is too restrictive and technical definition of nanomedicine.

why cancer samples from different patients responded differently to drugs?

Targeting as you presented it is important for us in Chem / Bio Defense, too. As is the comment about comparing to standard of care.

@Kien - differences in intratumoral distribution and cancer cell heterogeneity are among key factors

Thanks Prof Park for the interesting seminar!

Great kickoff to this new series.